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Abstract: 
Introduction: Renal carcinoid tumor is an extremely rare neoplasia. It arises from neuroendocrine cells, which have never 
been identified within the normal renal parenquima. After diagnosis, which is usually histological and proceeds 
nephrectomy, it is therefore important to exclude a primary tumor located elsewhere. Somatostatin receptor scintigraphy is a 
fundamental test in identification of primary tumor/metastases.  
Presentation of Case: We present a 77 year old man with this rare tumor: a primary carcinoid renal tumor, diagnosed in 
Portugal. He was asymptomatic and staging revealed no metastases. A partial nephrectomy was performed. After 2 years of 
follow up there is no evidence of clinic or imagiologic recurrence. 
Conclusion: There are no neuroendocrine cells within renal parenquima. Thus primary renal carcinoid is still a mystery. Our 
case confirms the existence of this entity and allows us to know more about its natural history. It is important to disclose all 
cases of this rare condition, so we can better treat these patients in the future. 
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Introduction 
Carcinoid tumors are defined as well differentiated 
neuroendocrine tumors [1,2]. These tumors are rare and 
arise from neuroendocrine cells that are dispersed 
throughout the body [3]. They are commonly seen in 
gastrointestinal tract, lungs and pancreas and less 
frequently in larynx, trachea, breast, biliary duct, 
gallbladder, ovaries, testis, prostate and kidney [2]. 
Renal carcinoid tumor (RCT), such as carcinoid 
tumors in other locations, arises from neuroendocrine 
cells. However these cells have never been identified 
within the normal renal parenquima. In genitourinary 
system, neuroendocrine cells were identified only in 
bladder and prostate [8]. Several theories exist about the 
origin of primary RCT, as discussed later. 
Because of its rarity (less than 1% of carcinoid 
tumors), after diagnosis it’s important to exclude a 
primary tumor located elsewhere [1].  The set of 
complementary tests that should be done include 
neuroendocrine serum markers (NSM), computed 
tomography (CT) or magnetic resonance imaging (MRI) 
and somatostatin receptor scintigraphy (SRS) with 
octeotride. These tests also allow staging the tumor [2]. 
Case Presentation  
A 77 year old man presented to us with a CT scan 
showing a mass with a 3,5 cm diameter, located in the 
inferior pole of right kidney. He was asymptomatic. 
Staging with CT revealed no metastases. A partial 
nephrectomy was performed and microscopy showed 
that it was a well differentiated renal carcinoid.  
Throughout this result, some complementary exams 
were required: NSM, upper endoscopy and colonoscopy, 
thorax radiography and SRS.  Upper endoscopy and 
colonoscopy excluded primary intestinal tumor. Analysis 
revealed an elevation on 5-hydroxyndolacetic acid 
(5-HIAA) - 19.8mg/24h (reference range 2-6mg/24h) - 
and vanillylmandelic acid - 18.1mg/24h (reference range 
2-7mg/24h). SRSO revealed a pancreatic foci suspicious 
of primary tumor or physiologic uptake (Figure 1). 
Pancreatic magnetic resonance was immediately 
performed, excluding primary pancreatic tumor. 
After 2 years of follow up, our patient remains 
asymptomatic and there is no evidence of imagiologic 
recurrence. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Somatostatin receptor scintigraphy showing the pancreatic foci suspicious of primary tumor or physiologic 
uptake 
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Discussion 
RCT has been reported in literature as case reports 
and small reviews only. No randomised studies 
have been published about it [4]. Less than 100 
cases have been described so far, in literature [1, 3, 
and 4]. The first case was reported in 1966, by 
Rensick et al [5]. We found only one portuguese 
case published [6].   
The reason for this is probably related with the 
low prevalence of this tumor. Less than 1% of 
carcinoid tumors are primary genitourinary tumors 
and primary RCT are among the most unusual of 
all renal neoplasms [3]. Consequently, RCT 
pathogenesis, clinical behaviour, treatment and 
follow up are not well established yet. 
RCT pathogenesis is a controversial issue, once 
neuroendocrine cells have never been identified in 
kidney parenquima, but several mechanisms have 
been hypothesized. It is believed that RCT may 
arise from primitive pluripotential stem cells that 
differentiate into aberrant neuroendocrine cells [4]. 
Another theory says that RCT arise from 
pre-existing or acquired hiperplasia of 
neuroendocrine cells found within foci of 
metaplastic or teratomatous epithelium [7]. And a 
third theory says that neuroendocrine cells derive 
from misplaced neural crests or pancreatic tissue 
within the metanephros during embryogenesis [3, 
7]. The latest theories probably emerged from the 
finding of a higher prevalence of horseshoe kidney 
and teratomas, among patients with RCT.  
The age of RCT diagnosis ranges between the 
fifth and sixth decades of life, with older age 
representing a bad prognosis factor. The incidence 
between genders has no relevant difference [4]. 
About a half of patients presents haematuria or 
flank/abdominal pain, 20% are asymptomatic, 15% 
have constitutional symptoms and only 13% 
presents with carcinoid syndrome [2, 7, 8]. In the 
future, with development of imaging, especially 
ultrasound, more RCT as other renal masses, will 
probably be incidentally detected [3]. That’s the 
case of our patient, as described above.  
RCT is difficult to distinguish from renal 
carcinoma pre-operatively, so final diagnosis is 
always histopathological [7].  However, 
histopathological examination is not sufficient to 
distinguish whether the tumor is a primary RCT or 
a metastasis [3]. 
Somatostatin receptor scintigraphy is recognised 
as an integral diagnosing and staging tool in the 
evaluation of carcinoid tumors. These tumors have 
high affinity receptors for somatostatin [9]. The 
radiolabeled octeotride (synthetic and slowly 
degraded somatostatin analog) binds somatostatin 
receptor with high affinity, detecting even the 
smallest carcinoid tumors with 85% sensitivity [2]. 
SRS use is therefore mandatory on RCT diagnosis, 
initially to exclude a primary tumor in another 
location and later, at follow up, to detect 
metastases. 
The RCT natural history and prognosis are not 
well understood, but outcome from published 
literature suggests that it has a less aggressive 
behavior than renal cell carcinoma [1, 3]. The 
major bad prognostic factors are age above 40 
years, tumor size over 4 cm and tumors not 
confined to the renal parenchyma [3].   
Metastases are rare. The most common sites are 
paraortic or hilar lymph nodes, followed by liver, 
bone and lung. The presence of metastases seems 
to be a bad prognostic factor, although some 
patients with solid organ metastatic disease lived 
for several years [3]. 
Surgical treatment (total or partial nephrectomy) 
is the primary approach and it’s apparently curative 
for localized disease [7]. Metastases, when present, 
and if possible, should also be removed or ablated, 
such as in other carcinoid tumors [1]. Cytotoxic 
chemotherapy has only limited success in treatment 
of metastatic disease. Somatostatin analogues like 
octeotride or lanreotide have been used in 
advanced disease with a response rate of 36-70% 
[1]. Octeotride not only plays an important role in 
decreasing the symptoms of hormonal excess but 
also is considered as a first line antineoplasic 
systemic therapy for patients with positive SRS [3]. 
Follow up should always exceed 5 years, 
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including physical examination, NSM and imaging 
(CT or MRI, complemented with SRS), every 3 to 
6 months [3]. 
Conclusion 
Primary RCT, despite its rarity an unknown 
aetiology, exists as a clinical entity. Our patient 
represents one of these rare cases, and fits in the 
literature review. Long-term studies are needed to 
determinate the exact clinical behavior and 
effective treatments for this rare tumor. 
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